In the Toprol case, Faruqi & Faruqi, LLP represents a pharmaceutical wholesaler and a class of direct purchasers of AstraZeneca’s branded drug Toprol XL (extended-release metoprolol succinate). The case alleges that AstraZeneca fraudulently procured two patents and filed multiple baseless patent infringement lawsuits using those patents, solely in an effort to delay less-expensive generic competition, a violation of § 2 of the Sherman Act. A $20 million settlement in the case has been approved by the court, and final judgment has been entered.
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.
Filed on 06/05/2006
1617 JFK Boulevard, Suite 1550
19103 Philadelphia, Pennsylvania
Phone (215) 277-5770
Fax (215) 277-5771
Peter Kohn email@example.com Phone (215) 277-5770 Fax (215) 277-5771